FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4294798294> ?p ?o ?g. }

• W4294798294 endingPage "e877" @default.
• W4294798294 startingPage "e870" @default.
• W4294798294 abstract "Abstract Purpose Aldo-keto reductase family 1 member C3 (AKR1C3) is important in prostate cancer progression, being a potential biomarker in metastatic castration-resistant prostate cancer (mCRPC). Previous explorations of AKR1C3 are mainly based on tissue samples. This study investigates using plasma-based liquid biopsy to validate the prognostic and predictive value of AKR1C3 in patients with mCRPC . Materials and Methods We prospectively recruited 62 patients with mCRPC. All patients received repeated prostate biopsies at the time of mCRPC diagnosis, and immunohistochemistry (IHC) staining was used to detect protein expression of AKR1C3 in the tissues. We took their blood simultaneously and performed digital droplet polymerase chain reaction (ddPCR) to measure expression levels of AKR1C3 in the exosomes. The detected plasma and tissue AKR1C3 expression levels were analyzed for patients’ overall survival (OS) and progression-free survival under first-line abiraterone use (ABI-PFS). Results All other baseline characteristics were balanced between the 2 groups. 15/62 (24.2%) and 25/62 (40.3%) patients showed AKR1C3-EXO positive (≥20 copies/20 μL) and AKR1C3-IHC positive, respectively. Positive AKR1C3-EXO expression was associated with decreased patients’ survival [ABI-PFS: 3.9 vs 10.1 months, P &lt; .001; OS: 16.2 vs 32.5 months, P &lt; .001]. AKR1C3-IHC positivity was also correlated with ABI-PFS and OS (P = .010, P = .016). In patients with worse baseline blood tests (including higher alkaline phosphatase (ALP) and lactate dehydrogenase (LDH) level and lower hemoglobin (HB) level), and lower ISUP/WHO group (&lt;4), their OS was significantly worse when showing AKR1C3-EXO positive. Conclusion AKR1C3-EXO is associated with patient prognosis regarding OS and ABI-PFS and can be used as a biomarker in mCRPC." @default.
• W4294798294 created "2022-09-06" @default.
• W4294798294 creator A5010446878 @default.
• W4294798294 creator A5011949034 @default.
• W4294798294 creator A5017294775 @default.
• W4294798294 creator A5018417778 @default.
• W4294798294 creator A5025567893 @default.
• W4294798294 creator A5026111867 @default.
• W4294798294 creator A5026468444 @default.
• W4294798294 creator A5028847615 @default.
• W4294798294 creator A5030769859 @default.
• W4294798294 creator A5034470550 @default.
• W4294798294 creator A5037874610 @default.
• W4294798294 creator A5042481304 @default.
• W4294798294 creator A5047871723 @default.
• W4294798294 creator A5052689516 @default.
• W4294798294 creator A5065096073 @default.
• W4294798294 creator A5065935918 @default.
• W4294798294 creator A5075732221 @default.
• W4294798294 date "2022-09-06" @default.
• W4294798294 modified "2023-10-17" @default.
• W4294798294 title "Plasma Exosomal AKR1C3 mRNA Expression Is a Predictive and Prognostic Biomarker in Patients with Metastatic Castration-Resistant Prostate Cancer" @default.
• W4294798294 cites W1551341102 @default.
• W4294798294 cites W1821596905 @default.
• W4294798294 cites W2007334137 @default.
• W4294798294 cites W2077301757 @default.
• W4294798294 cites W2098193929 @default.
• W4294798294 cites W2099477169 @default.
• W4294798294 cites W2118385994 @default.
• W4294798294 cites W2121076737 @default.
• W4294798294 cites W2133650808 @default.
• W4294798294 cites W2153737103 @default.
• W4294798294 cites W2466655046 @default.
• W4294798294 cites W2530715453 @default.
• W4294798294 cites W2539520833 @default.
• W4294798294 cites W2754675042 @default.
• W4294798294 cites W2762087180 @default.
• W4294798294 cites W2808349648 @default.
• W4294798294 cites W2900756811 @default.
• W4294798294 cites W2943208181 @default.
• W4294798294 cites W2956871921 @default.
• W4294798294 cites W2980245695 @default.
• W4294798294 cites W3010661136 @default.
• W4294798294 cites W3031093253 @default.
• W4294798294 cites W3046488036 @default.
• W4294798294 cites W3080468866 @default.
• W4294798294 cites W3137537012 @default.
• W4294798294 cites W3183660675 @default.
• W4294798294 cites W3192736942 @default.
• W4294798294 cites W4210734389 @default.
• W4294798294 doi "https://doi.org/10.1093/oncolo/oyac177" @default.
• W4294798294 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36067250" @default.
• W4294798294 hasPublicationYear "2022" @default.
• W4294798294 type Work @default.
• W4294798294 citedByCount "2" @default.
• W4294798294 countsByYear W42947982942023 @default.
• W4294798294 crossrefType "journal-article" @default.
• W4294798294 hasAuthorship W4294798294A5010446878 @default.
• W4294798294 hasAuthorship W4294798294A5011949034 @default.
• W4294798294 hasAuthorship W4294798294A5017294775 @default.
• W4294798294 hasAuthorship W4294798294A5018417778 @default.
• W4294798294 hasAuthorship W4294798294A5025567893 @default.
• W4294798294 hasAuthorship W4294798294A5026111867 @default.
• W4294798294 hasAuthorship W4294798294A5026468444 @default.
• W4294798294 hasAuthorship W4294798294A5028847615 @default.
• W4294798294 hasAuthorship W4294798294A5030769859 @default.
• W4294798294 hasAuthorship W4294798294A5034470550 @default.
• W4294798294 hasAuthorship W4294798294A5037874610 @default.
• W4294798294 hasAuthorship W4294798294A5042481304 @default.
• W4294798294 hasAuthorship W4294798294A5047871723 @default.
• W4294798294 hasAuthorship W4294798294A5052689516 @default.
• W4294798294 hasAuthorship W4294798294A5065096073 @default.
• W4294798294 hasAuthorship W4294798294A5065935918 @default.
• W4294798294 hasAuthorship W4294798294A5075732221 @default.
• W4294798294 hasBestOaLocation W42947982941 @default.
• W4294798294 hasConcept C121608353 @default.
• W4294798294 hasConcept C126322002 @default.
• W4294798294 hasConcept C143998085 @default.
• W4294798294 hasConcept C181199279 @default.
• W4294798294 hasConcept C204232928 @default.
• W4294798294 hasConcept C2776235491 @default.
• W4294798294 hasConcept C2777318727 @default.
• W4294798294 hasConcept C2780192828 @default.
• W4294798294 hasConcept C2781197716 @default.
• W4294798294 hasConcept C55493867 @default.
• W4294798294 hasConcept C71924100 @default.
• W4294798294 hasConcept C86803240 @default.
• W4294798294 hasConceptScore W4294798294C121608353 @default.
• W4294798294 hasConceptScore W4294798294C126322002 @default.
• W4294798294 hasConceptScore W4294798294C143998085 @default.
• W4294798294 hasConceptScore W4294798294C181199279 @default.
• W4294798294 hasConceptScore W4294798294C204232928 @default.
• W4294798294 hasConceptScore W4294798294C2776235491 @default.
• W4294798294 hasConceptScore W4294798294C2777318727 @default.
• W4294798294 hasConceptScore W4294798294C2780192828 @default.
• W4294798294 hasConceptScore W4294798294C2781197716 @default.
• W4294798294 hasConceptScore W4294798294C55493867 @default.
• W4294798294 hasConceptScore W4294798294C71924100 @default.

• next